- Home
- CNK vs IMVT Comparison
CNK vs IMVT Comparison
Compare CNK & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNK
- IMVT
- Stock Information
- Founded
- CNK 1984
- IMVT 2018
- Country
- CNK United States
- IMVT United States
- Employees
- CNK N/A
- IMVT N/A
- Industry
- CNK Movies/Entertainment
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CNK Consumer Discretionary
- IMVT Health Care
- Exchange
- CNK Nasdaq
- IMVT Nasdaq
- Market Cap
- CNK 3.2B
- IMVT 2.8B
- IPO Year
- CNK 2007
- IMVT N/A
- Fundamental
- Price
- CNK $30.25
- IMVT $16.95
- Analyst Decision
- CNK Buy
- IMVT Buy
- Analyst Count
- CNK 12
- IMVT 10
- Target Price
- CNK $33.00
- IMVT $40.14
- AVG Volume (30 Days)
- CNK 4.4M
- IMVT 1.4M
- Earning Date
- CNK 08-01-2025
- IMVT 08-05-2025
- Dividend Yield
- CNK 1.04%
- IMVT N/A
- EPS Growth
- CNK 16.58
- IMVT N/A
- EPS
- CNK 1.71
- IMVT N/A
- Revenue
- CNK $3,011,000,000.00
- IMVT N/A
- Revenue This Year
- CNK $9.66
- IMVT N/A
- Revenue Next Year
- CNK $7.27
- IMVT N/A
- P/E Ratio
- CNK $17.91
- IMVT N/A
- Revenue Growth
- CNK N/A
- IMVT N/A
- 52 Week Low
- CNK $20.43
- IMVT $12.72
- 52 Week High
- CNK $36.28
- IMVT $34.47
- Technical
- Relative Strength Index (RSI)
- CNK 46.24
- IMVT 60.86
- Support Level
- CNK $29.52
- IMVT $15.80
- Resistance Level
- CNK $31.00
- IMVT $17.06
- Average True Range (ATR)
- CNK 0.92
- IMVT 0.68
- MACD
- CNK -0.19
- IMVT 0.07
- Stochastic Oscillator
- CNK 34.69
- IMVT 86.70
About CNK Cinemark Holdings Inc Cinemark Holdings Inc.
Cinemark Holdings Inc is a geographically diverse operator in the motion picture exhibition industry in the United States. The company generates revenue from filmed entertainment box office receipts and concession sales, with additional revenue from screen advertising, screen rentals, and other revenue streams, such as transactional fees, vendor marketing promotions, studio trailer placements, meeting rentals, and electronic video games located in some of the theatres.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.